109 related articles for article (PubMed ID: 33030731)
21. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells.
Vogl FD; Stickeler E; Weyermann M; Köhler T; Grill HJ; Negri G; Kreienberg R; Runnebaum IB
Oncology; 1999 Nov; 57(4):324-9. PubMed ID: 10575320
[TBL] [Abstract][Full Text] [Related]
22. [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
Shi HR; Zhang RT
Ai Zheng; 2009 Aug; 28(8):882-5. PubMed ID: 19664338
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
24. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
[TBL] [Abstract][Full Text] [Related]
25. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
26. p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
Tsai-Turton M; Santillan A; Lu D; Bristow RE; Chan KC; Shih IeM; Roden RB
Gynecol Oncol; 2009 Jul; 114(1):12-7. PubMed ID: 19398128
[TBL] [Abstract][Full Text] [Related]
27. [Metabolic activity of peripheral blood neutrophils in women with ovarian tumours].
Kondera-Anasz Z; Mielczarek-Palacz A; Switała J; Piasecka A
Ginekol Pol; 2004 Aug; 75(8):609-14. PubMed ID: 15517784
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
[TBL] [Abstract][Full Text] [Related]
29. [A study on P16 and P53 protein expressions in ovarian serous cystadenocarcinoma].
Wang J; Zhang S; Wang S; Li F
Hua Xi Yi Ke Da Xue Xue Bao; 1997 Dec; 28(4):417-9, 423. PubMed ID: 10683958
[TBL] [Abstract][Full Text] [Related]
30. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
Vogl FD; Frey M; Kreienberg R; Runnebaum IB
Br J Cancer; 2000 Nov; 83(10):1338-43. PubMed ID: 11044359
[TBL] [Abstract][Full Text] [Related]
31. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
[TBL] [Abstract][Full Text] [Related]
32. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
33. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
34. [Assessment of cell proliferation based on group analysis of Ki-67 index in serous ovarian cancers].
Blok R; Blok K; Gryboś M; Klimkiewicz D; Jeleń-Krzeszewska J; Latkowski K
Ginekol Pol; 2004 Oct; 75(10):776-84. PubMed ID: 15587909
[TBL] [Abstract][Full Text] [Related]
35. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
Leffers N; Vermeij R; Hoogeboom BN; Schulze UR; Wolf R; Hamming IE; van der Zee AG; Melief KJ; van der Burg SH; Daemen T; Nijman HW
Int J Cancer; 2012 Jan; 130(1):105-12. PubMed ID: 21328579
[TBL] [Abstract][Full Text] [Related]
36. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.
Vennegoor CJ; Nijman HW; Drijfhout JW; Vernie L; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Verheijen RH; Kast WM; Melief CJ; Kenemans P
Cancer Lett; 1997 Jun; 116(1):93-101. PubMed ID: 9177463
[TBL] [Abstract][Full Text] [Related]
37. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
38. [Paraneoplastic cerebellar degeneration (PCD) with anti-Yo antibodies in ovarian carcinoma].
Holzmann P; Holy D; Stillhard G; Janda M; Möbr P
Schweiz Med Wochenschr; 1998 Jun; 128(23):906-8. PubMed ID: 9658519
[TBL] [Abstract][Full Text] [Related]
39. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
Garziera M; Montico M; Bidoli E; Scalone S; Sorio R; Giorda G; Lucia E; Toffoli G
PLoS One; 2015; 10(10):e0140351. PubMed ID: 26451959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
